Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124

Q3 FY20 results · Oct–Dec 2019

Dr. Reddy's Laboratories reported revenue from operations of ₹4,397.10 crore (up 13.8% from Q3 FY19) and net loss of ₹538.40 crore for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	4,397.10	3,864.60	+13.8%	4,812.80	−8.6%
Other income	67.30	102.30	−34.2%	54.00	+24.6%
Total income	4,464.40	3,966.90	+12.5%	4,866.80	−8.3%
Profit before share of associates & JVs and tax	(523.50)	592.50	Turned loss	774.40	Turned loss
Share of profit/(loss) of associates & JVs	17.60	8.90		11.70
Net profit for the period	(538.40)	500.30	Turned loss	1,106.80	Turned loss
EPS, basic (₹)	(32.48)	30.16	Turned loss	66.78	Turned loss
Net margin (%)	-12.2	12.9		23.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	3,044.00	2,731.70	+11.4%	3,446.00	−11.7%
Other income	69.30	92.80	−25.3%	76.70	−9.6%
Total income	3,113.30	2,824.50	+10.2%	3,522.70	−11.6%
Profit before tax	617.50	570.40	+8.3%	1,021.20	−39.5%
Net profit for the period	521.70	399.40	+30.6%	1,365.10	−61.8%
EPS, basic (₹)	31.47	24.08	+30.7%	82.36	−61.8%
Net margin (%)	17.1	14.6		39.6

Consolidated

Filed with BSE: 27 Jan 2020, 15:15 IST
Board meeting: 27 Jan 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 27 Jan 2020, 15:15 IST
Board meeting: 27 Jan 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE